Blog

Investing in Biotech Startups can be one of the most rewarding—and riskiest—decisions you make. Breakthrough therapies and innovative diagnostics can deliver strong returns, but the industry is complex and technical.

Unlike other industries, Biotech Startups often require deep scientific understanding to evaluate properly. Complex lab data, preclinical studies, and regulatory hurdles make it difficult to know whether the underlying science is sound.

This guide will help you evaluate Biotech Startups before investing, so you can make informed, confident decisions.

1. Understand the Science in Biotech Startups

Look for clarity in how the startup explains its science. Can they describe it in understandable terms? Are their results published, peer-reviewed, or at least presented in detail? Is their approach truly novel or just an incremental improvement?

Be cautious of companies that rely on jargon without explaining their work clearly.

2. Assess the Biotech Startup Team’s Expertise

A strong idea needs the right team to execute. Review the team’s scientific credentials and industry experience. Have they successfully developed products before? Is there expertise in regulatory approval and commercialization?

The right team is essential for turning promising science into viable products.

3. Evaluate Technical Feasibility of Biotech Startups

Not all ideas can be scaled or manufactured cost-effectively. Assess whether the company’s approach is technically feasible at scale. Consider stability, delivery mechanisms, and whether their development timeline is realistic.

Feasibility is often overlooked but can make or break a project.

4. Review the Regulatory Strategy for Biotech Startups

Biotech is heavily regulated. Understand the company’s plan for meeting regulatory requirements. Do they know which agencies they’ll work with? Are they aware of the necessary clinical phases? Do they have a realistic budget and timeline for approval?

A vague or unrealistic regulatory plan is a common red flag.

5. Analyze the Market Potential for Biotech Startups

Even if the science works, will there be demand? Evaluate the target patient population, unmet needs, existing competitors, and payer coverage.

Strong Biotech Startups will have solid answers to these questions, supported by data.

6. Conduct Rigorous Scientific Due Diligence on Biotech Startups

This is critical. Review the underlying data carefully. Verify claims with independent experts if needed. Assess the risk of failure at each development stage.

If you don’t have the in-house expertise, consider working with specialized firms that conduct scientific due diligence for Biotech Startups.

7. Examine Financial Planning for Biotech Startups

Biotech development is capital intensive. Check whether the company’s financial projections are realistic. How much funding will they need to reach key milestones? Is there a clear plan for using investor funds?

Understand the risk of dilution in future funding rounds.

Final Thoughts on Investing in Biotech Startups

Investing in Biotech Startups requires balancing innovation potential with careful risk management. Don’t be swayed by marketing hype. Take a structured approach:

• Evaluate the science critically
• Assess the team’s expertise
• Check technical feasibility
• Understand the regulatory plan
• Analyze market demand
• Conduct thorough scientific due diligence
• Review the financial plan carefully

At Biotech Insight Solutions, we specialize in helping investors make informed, confident decisions through detailed scientific due diligence and risk assessment for Biotech Startups.

If you’d like to learn more about how we support investors, get in touch with us here.

Investing in biotech can bring high rewards—but also significant risks. The biotech sector is complex, and a company’s success depends on multiple factors, including scientific research, clinical trial results, management, and financial support. Here are essential tips to help you make an informed decision before investing in a biotech company.

1. Evaluate the Scientific Foundation and Technology Platform

Start by examining its scientific foundation and technology platform. Look for innovations and the scientific achievements that back them. Patents or intellectual property protection are vital indicators that the company’s developments are well-protected.

2. Review Clinical Trial Results

Clinical trials are often a key indicator of a biotech company’s progress. Check if the company has a clear strategy for advancing through each phase of clinical trials. The closer they are to completing these stages, the less risk there is for investors. Dive into trial results, methodologies, and sample sizes for a thorough understanding.

3. Assess the Management Team

A capable and experienced team can make a significant difference in the company’s success. Review the backgrounds of the leadership and scientific advisors, and look for proven experience in biotechnology and past successes. A strong, reliable team often increases a company’s chance of successful growth and development.

4. Analyze Financial Stability

Financial health is a cornerstone of any viable investment. Look into the company’s revenue, expenses, debts, and funding sources. Ensuring that they have adequate resources to support ongoing research and clinical trials is crucial.

5. Assess Market Potential and Competition

Investigate the market that the company serves and evaluate its potential customer base. Look at competitors and their advancements to gauge how unique and in-demand the company’s technology is. A company with strong competitive advantages is better positioned for long-term success.

6. Take a Closer Look at the Company’s Reputation and Its Partners

When considering a biotech investment, don’t overlook the company’s reputation and the quality of its partnerships. Positive reviews, solid partnerships, and affiliations with respected institutions can be good indicators of a company’s stability and reliability. These connections often speak volumes about the company’s standing in the industry, so take the time to dig a little deeper.

7. Get Expert Help for Thorough Due Diligence

Biotech investments aren’t simple, especially with the involvement of scientific data and potential risks. If interpreting this information feels daunting, it’s well worth consulting with experts who specialize in due diligence. Having a professional guide can save you from costly mistakes and help you zero in on projects with solid, trustworthy foundations.

Final Thoughts

Biotech investing can be incredibly rewarding. On the other hand, it’s also full of complexities. Taking the time to research is essential for finding the right opportunities. When needed, bringing in expert advice can make the process even more effective. In this industry, solid and reliable companies are the ones that truly show their worth over time. Big promises might sound appealing, but they often fall short. By focusing on companies with a strong foundation, you’re setting yourself up for steady, long-term success.

In today’s biotech world, science has become incredibly complex and multi-layered. Published results are often taken as gospel, but the reality is that you can’t always rely on the conclusions of papers and studies. Recent research shows alarming statistics: many scientific studies cannot be reproduced. In 2016, a study published in Nature found that most scientists had difficulty reproducing the results of their own and other people’s experiments. In 2024, a study on the topic confirmed that problems with reproducibility persist in the biomedical field and affect the credibility of research.

This is especially important for biotech investors. Investing in a project with an unstable scientific base carries enormous risks. In an environment where many research results are difficult or impossible to reproduce, rigorous scientific verification through due diligence is essential for informed investment decisions.

The Role of Expertise in a World of Complex Data

Preparing to invest in biotech requires a deep understanding not only of the specific science, but also of the reliability of the research methodology. Numerous factors can lead to a research result being non-reproducible: pressure to publish, limited resources to validate experiments, statistical errors, or even bias. In such situations, it is important to have a trusted expert who will conduct a detailed analysis of the data to identify the potential and weaknesses of each project.

Professional analysis helps to identify both the real prospects of the project and possible pitfalls. Such support, like a reliable guide, points the investor to projects that have solid scientific evidence and prospects, and helps to avoid those that do not have a reliable basis.

Support in Making Investment Decisions

In order to invest in biotechnology successfully, one must have faith in its dependability in addition to an interest in science. Careful scientific research is necessary to obtain this level of assurance in a setting where many studies are still non-reproducible. Expert due diligence enables businesses to see past the statistics and distinguish between projects that are merely false prospects and those that have potential.

Having a trustworthy partner who can decipher complicated scientific data aids investors in making wise decisions, conserving money, and preventing losses. Relying on reproducible and effective scientific evidence is crucial when investing in biotechnology, which is a long-term endeavour.

References:

Cobey KD, Ebrahimzadeh S, Page MJ, Thibault RT, Nguyen PY, Abu-Dalfa F, Moher D. Biomedical researchers’ perspectives on the reproducibility of research. PLoS Biol. 2024 Nov 5;22(11):e3002870. doi: 10.1371/journal.pbio.3002870. PMID: 39499707; PMCID: PMC11537370.

Baker, M. 1,500 scientists lift the lid on reproducibility. Nature 533, 452–454 (2016). https://doi.org/10.1038/533452a

The biotech sector has been awash in the news lately, with companies shutting down, venture capitalists becoming increasingly cautious, and the overall market mood looking subdued. But as the saying goes, the darkest night is just before the dawn. And in 2024, there are signs that the sector may finally be starting to recover from its long decline.

An article in Nature Biotechnology titled “Funding Biotech: The Darkest Hour Before the Dawn” discusses the challenges the industry has faced over the past three years and points to emerging trends for recovery.

Three Years of Decline: Why Is Biotech in Crisis?

The biotech sector’s situation began to deteriorate back in 2021 when the COVID-19 boom ended. At that time, biotech companies were literally swimming in cash, raising millions of dollars to develop new drugs and technologies. However, with the end of the pandemic, the funding dried up, and the market began to decline.

The problems were exacerbated by rising interest rates and cautious investors, who now prefer to invest in more stable and safe assets. The public company market is also not conducive to optimism: most biotech stock prices remain low, and new IPOs are almost non-existent.

Light at the End of the Tunnel: Signs of Recovery

Despite all the difficulties, 2024 has brought some positive signs. Large investment firms such as Flagship Pioneering and Foresite Capital have started to create new biotech funds. Successful IPOs such as CNS-focused Rapport Therapeutics have raised significant funds and shown that investors are starting to pay attention to biotech companies again.

In addition, investors are focusing on late-stage projects that can already boast of early clinical results. This helps such companies to raise large sums and make deals with large pharma manufacturers.

The article highlights that the average size of funding rounds has increased over the past six months: venture capitalists prefer to invest in more mature companies with proven teams and interesting developments. This leads to the fact that one successful startup can raise tens of millions of dollars, while less successful projects are forced to close or seek funds on less favourable terms.

New Trends: What Attracts Investors?

In the current environment, investors are actively investing in several hot areas. Among them:

• Immunotherapy and anticancer drugs: Companies working on the creation of antibody-drug conjugates (ADC), radioisotope therapies and drugs for the treatment of oncological diseases remain in the focus of large pharmaceutical companies and venture capitalists.
• Technologies using artificial intelligence: Startups using AI and machine learning to develop new drugs and improve research are also attracting significant investments. For example, in April 2024, Xaira Therapeutics raised $1 billion in early-stage funding.
• Chinese Biotech: Despite political instability and tensions with Western countries, Chinese biotechs are becoming increasingly attractive to foreign investors. This is due to the high rate of innovation and relatively low valuations compared to Western companies.

European Companies: How to Survive in a Funding Shortage?

In Europe, the situation remains difficult. Local capital markets do not have the same depth as in the US, and the number of specialized venture capital funds is limited. As a result, many European startups are forced to either raise funds from public funds or seek strategic partners among corporations.

However, there are also positive examples. Companies like Asgard Therapeutics have managed to raise large funds thanks to the support of corporate venture funds and government programs. European companies are also gradually starting to attract American investors, especially in areas such as artificial intelligence and medical technology.

Is There Hope for an Upswing?

The biotech sector is certainly going through tough times. But, as in any cycle, there is growth after a downturn. If the positive trends continue in 2024 — growth in late-stage funding and the attention of large pharma companies — then biotech companies will be able to emerge from the crisis stronger and more adapted to the new reality.

The most important thing to remember is that even in the most difficult times, some projects and teams find opportunities for growth and development. And today’s situation is not the end but only a stage on the way to a new, more stable and healthy biotech sector.

Reference:
Senior, M. Biotech financing: darkest before the dawn. Nat Biotechnol 42, 1331–1338 (2024). https://doi.org/10.1038/s41587-024-02357-2